Abstract |
BO-653 is an antioxidant under development by Chugai for the potential treatment of atherosclerosis and the prevention of restenosis. By November 2001, BO-653 was in phase II trials for restenosis in post-percutaneous transluminal coronary angioplasty in the US, and by April 2002, the compound was in phase I trials for the same indication in Japan.
|
Authors | Charles Q Meng |
Journal | Current opinion in investigational drugs (London, England : 2000)
(Curr Opin Investig Drugs)
Vol. 4
Issue 3
Pg. 342-6
(Mar 2003)
ISSN: 1472-4472 [Print] England |
PMID | 12735236
(Publication Type: Journal Article, Review)
|
Chemical References |
- 2,3-dihydro-5-hydroxy-2,2-dipentyl-4,6-di-tert-butylbenzofuran
- Antioxidants
- Benzofurans
|
Topics |
- Animals
- Antioxidants
(pharmacology, therapeutic use)
- Arteriosclerosis
(drug therapy)
- Benzofurans
(pharmacology, therapeutic use)
- Clinical Trials, Phase I as Topic
- Clinical Trials, Phase II as Topic
- Coronary Restenosis
(prevention & control)
- Humans
|